| Summary: | Breast cancer is one of the many diseases that cause morbidity and
mortality. The prevalence of breast cancer is increasing worldwide including in
Indonesia along with increased life expectancy, socioeconomic, and changes in
disease patterns. More than half of patients with breast cancer was diagnosed in an
advanced stage when the tumor has had metastasis to the handling tends to be late
and only palliative.
The biology of breast cancer is complex, involving oncogenesis, evasion
of host immune defense mechanisms, angiogenesis, invasion and metastasis. So
far, interleukin-6, better known as cytokines that mediate inflammation and
activation of lymphocytes hematopoesis, but recent studies reported IL-6 has a
role as a mediator of tumor progression. IL-6 expression correlated with the
degree of tumor, and poor survival. The results of these studies enabled the
development of new therapeutic anti-IL-6 to improve the existing therapy.
This study is an observational analytic study with a cross-sectional design
to determine differences in levels of IL-6 at various clinical stages of breast
cancer. The subjects in this study were consecutive patients with suspected breast
cancer that visited the oncology clinic Tulip or pre-operative patients in the
surgical treatment of Dr. Sardjito hospital in Yogyakarta who fullfilled the
inclusion and exclusion criteria. Examination of IL-6 serum using a quantitative
sandwich electrochemiluminescence immunoassay method. The results shown in
the descriptive analysis and analysis of differences in levels at various clinical
stages.
|
|---|